MTOR and neoplasm: A subsequent TMA analysis revealed that elevated p-mTOR, instead of mTOR, was associated with tumor aggressiveness and impaired OS in 342 primary and 90 metastatic ccRCC patients, and univariate survival analysis displayed that elevated p-mTOR was a predictive marker of poor OS (Rausch et al., 2019), which validated our present study.